SCHEMBL17513207

SCHEMBL17513207

O=C(O)/C=C/Oc1ccc(Cl)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
PLA2G1B P04054 1/20 0.55
ATG4B Q9Y4P1 1/20 0.55
TDP1 Q9NUW8 2/20 0.51
KMT2A Q03164 1/20 0.48
TSHR P16473 2/20 0.46
TTR P02766 3/20 0.45
MRGPRX4 Q96LA9 2/20 0.44
ITGB2 P05107 1/20 0.44
ICAM1 P05362 1/20 0.44
ITGAL P20701 1/20 0.44
HPGD P15428 3/20 0.43
CYP1A2 P05177 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALOX12 P18054 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19378088 1.00 MAPT (0.55) MAPTPLA2G1BATG4BTDP1KMT2A
SCHEMBL17513208 1.00 MAPT (0.55) MAPTPLA2G1BATG4BTDP1KMT2A
SCHEMBL17513205 0.79 MAPT (0.54) MAPTTDP1KMT2ATSHRHPGD
SCHEMBL19377862 0.79 MAPT (0.54) MAPTTDP1KMT2ATSHRHPGD
SCHEMBL11623017 0.79 MAPT (0.54) MAPTTDP1KMT2ATSHRHPGD
SCHEMBL4657172 0.77 ALDH1A1 (0.41) MAPTPLA2G1BATG4BTDP1KMT2A
SCHEMBL4657171 0.77 ALDH1A1 (0.41) MAPTPLA2G1BATG4BTDP1KMT2A
SCHEMBL10809237 0.76 TDP1 (0.59) MAPTPLA2G1BATG4BTDP1TSHR
Triclosan SCHEMBL28659426 0.76 TTR (0.75) MAPTPLA2G1BATG4BTDP1TTR
SCHEMBL10809227 0.76 TDP1 (0.59) MAPTPLA2G1BATG4BTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 WO claimed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 US disclosed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE AARS1, MTR, GARS1 MAPT 3016/4885PLA2G1B 3750/4885ATG4B 3028/4885
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase AARS1, MTR, GARS1 MAPT 3016/4885PLA2G1B 3750/4885ATG4B 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.